PMID- 30925321
OWN - NLM
STAT- MEDLINE
DCOM- 20200114
LR  - 20200114
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 71
DP  - 2019 Jun
TI  - Inhibitory effect of taxifolin on mast cell activation and mast cell-mediated 
      allergic inflammatory response.
PG  - 205-214
LID - S1567-5769(18)30966-4 [pii]
LID - 10.1016/j.intimp.2019.03.038 [doi]
AB  - The aim of the present study is to investigate the anti-inflammatory and 
      anti-allergic effects of taxifolin on mast cells and mast cell-mediated allergic 
      reaction. We assessed the effect of taxifolin on the activation of bone 
      marrow-derived mast cells (BMMCs) and rat basophilic leukemia (RBL)-2H3 cells 
      induced by immunoglobulin E (IgE)/antigen (Ag), and the activation of human mast 
      cell line (HMC-1) induced by PMA plus A23187. Taxifolin inhibited degranulation, 
      generation of leukotriene C(4) (LTC(4)), production of interlukin-6 (IL-6), and 
      expression of cyclooxygenase-2 (COX-2) through blocking intracellular Ca(2+) 
      mobilization, phosphorylation of phospholipase Cgamma (PLCgamma) and mitogen-activated 
      protein kinases (MAPKs), translocation of cytosolic phospholipase A(2) (cPLA(2)) 
      and 5-lipoxygenase (5-LO), and Akt/IKK/NF-kappaB pathway, in BMMC cells. Furthermore, 
      taxifolin suppressed phosphorylation of Syk, but without effect on Fyn and Lyn. 
      Taxifolin also inhibited activation of RBL-2H3 and HMC-1 cells via Akt/IKK/NF-kappaB 
      and MAPKs/cPLA(2) signal pathway. Treatment with taxifolin attenuated the mast 
      cell-mediated passive cutaneous anaphylaxis (PCA) reaction. Our results suggest 
      that taxifolin might become a potential drug candidate for the treatment of 
      allergic and inflammatory diseases.
CI  - Copyright (c) 2019. Published by Elsevier B.V.
FAU - Pan, Shunli
AU  - Pan S
AD  - Tianjin Key Laboratory on Technologies Enabling Development of Clinical 
      Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, 
      Tianjin 300070, China.
FAU - Zhao, Xiaoxia
AU  - Zhao X
AD  - Tianjin Key Laboratory on Technologies Enabling Development of Clinical 
      Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, 
      Tianjin 300070, China.
FAU - Ji, Ning
AU  - Ji N
AD  - Tianjin Key Laboratory on Technologies Enabling Development of Clinical 
      Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, 
      Tianjin 300070, China.
FAU - Shao, Chen
AU  - Shao C
AD  - Tianjin Key Laboratory on Technologies Enabling Development of Clinical 
      Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, 
      Tianjin 300070, China.
FAU - Fu, Bingjie
AU  - Fu B
AD  - Tianjin Key Laboratory on Technologies Enabling Development of Clinical 
      Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, 
      Tianjin 300070, China.
FAU - Zhang, Zhe
AU  - Zhang Z
AD  - Tianjin Key Laboratory on Technologies Enabling Development of Clinical 
      Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, 
      Tianjin 300070, China.
FAU - Wang, Ran
AU  - Wang R
AD  - Tianjin Key Laboratory on Technologies Enabling Development of Clinical 
      Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, 
      Tianjin 300070, China.
FAU - Qiu, Yuling
AU  - Qiu Y
AD  - Tianjin Key Laboratory on Technologies Enabling Development of Clinical 
      Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, 
      Tianjin 300070, China.
FAU - Jin, Meihua
AU  - Jin M
AD  - Tianjin Key Laboratory on Technologies Enabling Development of Clinical 
      Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, 
      Tianjin 300070, China. Electronic address: jinmeihua@tmu.edu.cn.
FAU - Kong, Dexin
AU  - Kong D
AD  - Tianjin Key Laboratory on Technologies Enabling Development of Clinical 
      Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, 
      Tianjin 300070, China; Research Center, School of Medicine, Tianjin Tianshi 
      College, Tianyuan University, Tianjin 301700, China. Electronic address: 
      kongdexin@tmu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20190326
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (NF-kappa B)
RN  - 2CU6TT9V48 (Leukotriene C4)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 9IKM0I5T1E (Quercetin)
RN  - 9SOB9E3987 (taxifolin)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Cell Degranulation/drug effects
MH  - Cell Line
MH  - Cyclooxygenase 2/genetics/metabolism
MH  - Humans
MH  - Hypersensitivity/*drug therapy
MH  - Immunoglobulin E/metabolism
MH  - Inflammation/*drug therapy
MH  - Leukotriene C4/metabolism
MH  - Mast Cells/*drug effects
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - NF-kappa B/metabolism
MH  - Passive Cutaneous Anaphylaxis/*drug effects
MH  - Quercetin/*analogs & derivatives/therapeutic use
MH  - Rats
MH  - Signal Transduction
OTO - NOTNLM
OT  - Akt/IKK/NF-kappaB
OT  - Mast cell
OT  - PCA
OT  - Syk
OT  - Taxifolin
EDAT- 2019/03/30 06:00
MHDA- 2020/01/15 06:00
CRDT- 2019/03/30 06:00
PHST- 2018/10/24 00:00 [received]
PHST- 2019/03/03 00:00 [revised]
PHST- 2019/03/20 00:00 [accepted]
PHST- 2019/03/30 06:00 [pubmed]
PHST- 2020/01/15 06:00 [medline]
PHST- 2019/03/30 06:00 [entrez]
AID - S1567-5769(18)30966-4 [pii]
AID - 10.1016/j.intimp.2019.03.038 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2019 Jun;71:205-214. doi: 10.1016/j.intimp.2019.03.038. Epub 
      2019 Mar 26.